Drugs / Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform
Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06149481 | Mar 2024 → Oct 2027 expected | colorectal cancer | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06149481 ↗ |
| Modality | Vaccine | “The TriAdeno Vaccine employs 3 adenovirus serotype 5 vectors, encoding three TAAs (CEA, MUC1, and brachyury).” NCT06149481 ↗ |
| Route | Subcutaneous | “5x10\^11 virus particles per 1 mL administered via subcutaneous injection in the upper arm and anterolateral upper thigh” NCT06149481 ↗ |
| Target | MUC1 | “The TriAdeno Vaccine employs 3 adenovirus serotype 5 vectors, encoding three TAAs (CEA, MUC1, and brachyury).” NCT06149481 ↗ |